Fusion Antibodies plc, specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2019, the Notice of Annual General Meeting and a Form of Proxy will be posted to shareholders later.
21 August 2019
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, confirms that the Annual Report and Accounts for the year ended 31 March 2019 (‘2019 Annual Report and Accounts’), the Notice of Annual General Meeting (‘AGM’) and a Form of Proxy will be posted to shareholders later today.
The AGM will be held on 20 September 2019 at 11.00 a.m. at Riddel Hall, Queens University, 185 Stranmillis Road, Belfast BT9 5EE United Kingdom.
A copy of the 2019 Annual Report and Accounts will be available to download from the Company website shortly.
Enquiries:
Fusion Antibodies plc
www.fusionantibodies.com <http://www.fusionantibodies.c
Dr Paul Kerr, Chief Executive Officer
Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited
Tel: +44 (0)20 3328 5656
Walbrook PR
Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy
Mob: +44 (0)7876 741 001
Paul McManus
Mob: +44 (0)7980 541 893
